THEOCLEAR L.A.-130 Drug Patent Profile
✉ Email this page to a colleague
When do Theoclear L.a.-130 patents expire, and when can generic versions of Theoclear L.a.-130 launch?
Theoclear L.a.-130 is a drug marketed by Schwarz Pharma and is included in one NDA.
The generic ingredient in THEOCLEAR L.A.-130 is theophylline. There are thirty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Theoclear L.a.-130
A generic version of THEOCLEAR L.A.-130 was approved as theophylline by RHODES PHARMS on September 1st, 1982.
Summary for THEOCLEAR L.A.-130
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 171 |
Patent Applications: | 3,888 |
Formulation / Manufacturing: | see details |
DailyMed Link: | THEOCLEAR L.A.-130 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for THEOCLEAR L.A.-130
US Patents and Regulatory Information for THEOCLEAR L.A.-130
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schwarz Pharma | THEOCLEAR L.A.-130 | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 086569-001 | May 27, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |